Positive Serologic Test for Hepatitis B Virus (HBV)
Hepatitis B virus infection
False-positive serologic test for hepatitis B virus
Suggested Additional Lab Testing
Acute hepatitis B
Patient is positive for IgM antibody to HBV core antigen.
Patient is usually positive for hepatitis B surface antigen and hepatitis B virus e antigen. Presence of the e antigen indicates a high degree of infectivity.
Patient is likely to be positive for serum HBV DNA; level can be followed to assess response to therapy.
Chronic hepatitis B
Liver function tests, especially aminotransferases, are likely to be elevated for more than 6 months.
Hepatitis B surface antigen is positive for more than 6 months.
Chronic cases are also positive for anti-HBV core antigen as total antibody or as IgG.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma